 (J. Clin. Invest. 1994. 93:405416.)
Introduction
Fibronectin (FN)' is a ubiquitous extracellular matrix (ECM) protein that provides the architectural scaffolding in tissues and can also be found in body fluids such as plasma (for a review, see reference 1). Although FN is encoded by a single gene, FN polypeptide diversity is generated by alternative splicing of a primary FN RNA transcript (2) (3) (4) . Patterns of FN gene splicing are regulated in a cell type-specific fashion, and presumably play a central role in such dynamic processes as embryogenesis (5, 6), wound healing (7), viral transformation 1. Abbreviations used in this paper: D-PBS, Dulbecco's PBS; EC, endothelial cell; ECM, extracellular matrix; EM, electron microscopy; FN, fibronectin; HUVEC, human umbilical vein endothelial cell; OVA, ovalbumin; RA, rheumatoid arthritis; VCAM, vascular cell adhesion molecule.
The FN gene contains three separate exons that are subject to alternative splicing, termed EIIIA, EIIIB, and V or IIICS ( 1 ) . The presence of additional acceptor and donor splice signals within the IIICS region allows generation ofincreased diversity in FN by virtue ofmultiple IIICS polypeptide variants, namely, three in rat FN (2, 10) and five in human FN ( 11, 12) . One subset of these molecular variants expresses a 25-amino acid sequence termed CS 1 ( 13, 14) , which is a counter-receptor for the a4f31 (also known as VLA-4) integrin (15, 16) . To date, the VLA-4/CS1 interaction has been widely documented in hematopoiesis where adhesive interactions between hematopoietic progenitors expressing (17) (18) (19) (20) and their ECM microenvironment play a critical role in precursor maturation and differentiation. Thus, CS1 peptides have been shown to inhibit: (a) attachment of murine hematopoietic stem cells to ECM derived from bone marrow stroma ( 18) , (b) immunoglobulin secretion by bone marrow-derived B cell progenitors ( 19) , and (c) thymocyte adhesion and differentiation induced by thymic stromal cell monolayers (20, 21 ) . VLA-4/CS1 may also be involved in embyonic development, since CS 1 peptides have been shown to interfere with migration of avian neural crest cells (22) .
VLA-4, which is predominantly expressed on lymphocytes, monocytes, and eosinophils, but not on neutrophils ( 17) , also serves as a receptor for the cytokine-inducible vascular cell adhesion molecule type 1 (VCAM-1) (23, 24) . The dual interaction of VLA-4 on leukocytes with either endothelial VCAM-1, or CS 1-containing FN in the ECM, has been postulated to play a key role in leukocyte trafficking during inflammation (23, 25, 26) . In a murine model of contact hypersensitivity, CS1 peptide partially inhibited recruitment of T lymphocytes to skin inflammatory sites (27) . Since the Arg-Gly-Asp peptide from the cell adhesion domain of FN was also inhibitory in this animal model, the authors concluded that emigration of immune T cells to sites of antigenic challenge in the tissue could be facilitated by the interaction of leukocyte integrins with ECM proteins such as FN (27) . In conclusion, none of the studies reported to date offer a precedent for endothelial expression of CS 1-containing FN. Rheumatoid arthritis (RA) is a chronic inflammatory condition whereby a large number of mononuclear cells, mostly CD4 memory T cells (28) (29) (30) and macrophages, accumulate in perivascular areas within the synovial membrane (for reviews, see references 31 and 32) . Although significant accumulation of lymphocytes, monocytes, and neutrophils in the synovial fluid occurs, very few neutrophils actually infiltrate the synovial membrane itself ( 31, 32 (35) . All tissues were immediately snap frozen in 2-methyl-butane and liquid nitrogen, and stored at -700C until used. One normal synovium was obtained from a patient who had a total hip replacement to repair a nonhealing fracture, and four additional normal knee synovia were obtained at the time of autopsy from individuals without arthritis who died ofunrelated causes. The autopsy specimens were processed within 6 h of death.
mAbs, peptides, and cell lines. The following mAbs were used in this study: P4C2 (IgG3, anti-a4) (15) (43) . The tissues were then rinsed stepwise in PBS supplemented with increasing concentrations of sucrose (5, 10, 15, and 20% weight/vol) for 1 h at each concentration, followed by a final rinse with 25% sucrose, glycerol. At this point, tissues were snap frozen in OTC, sectioned at 4-Atm thickness, placed onto poly-L-lysine-coated (1 mg/ ml) methylpentene plates (Nunc, Naperville, IL), and finally rehydrated with 1% BSA in PBS. The tissues were then stained using the immunoperoxidase method as described above, and processed for routine electron microscopy (EM). Briefly, sections were fixed for 1 h with 2% glutaraldehyde, followed by 1% osmium tetroxide for 1 h on ice. Next, sections were dehydrated in a stepwise graded concentration of alcohol, and embedded in Spur plastic resin. The embedded tissues were removed from the methylpentene plates, and the synovial blood vessels and synovial lining area were identified and cut out with a jewelry hacksaw. These pieces were mounted onto blocks, and ultrathin en face sectioning (500 A) was performed. The ultrathin sections were viewed with an electron microscope (300; Philips Technologies, Torrance, CA).
Northern blot and ribonuclease protection analyses ofFN mRNA. Messenger RNA (4-10 X quence, the intact HeplI and CS1 radiolabeled probes were 436 and 150 nucleotides long, respectively. For Northern blot analysis, 1 'g mRNA/lane was separated on a 1% agarose/formaldehyde gel and transferred to a nitrocellulose membrane (Schleicher & Schuell, Inc., Keene, NH). Duplicate membranes were separately hybridized with the radiolabeled HepIl and CS I riboprobes ( 106 cpm/ ml, overnight at 550C). Stringent wash conditions (220C, l.Ox SSC; and 650C, 0.1 X SSC, twice, 30 min each) were used, followed by autoradiography. A 0.24-9.5-kb RNA ladder was used to determine approximate transcript sizes (Bethesda Research Laboratories, Gaithersburg, MD). For each ribonuclease protection assay, radiolabeled probe (-8.7 X 104 cpm) and IL-lfl-treated HUVEC mRNA (0.25 Mig) were used with ribonuclease protection assay reagents (RPA II; Ambion, Austin, TX). Various digestion conditions were tested for the assay, and Fig. 4 B shows results using a 1: 1,000 dilution of a stock containing RNase A (33.3 Kunitz U/ml) and RNase Tl (10,000 U/ml). Protected RNA fragments were separated on a 6% polyacrylamide/8 M urea gel using standard techniques (44) , and visualized by autoradiography.
Cell adhesion assay on synovialfrozen sections. The assay was modified from the original method of Stamper and Woodruff (45 Methods) . All of these mAbs bound to the intact 25-amino acid CS1 peptide (not shown), but more importantly, they exhibited well-defined sequence specificity as demonstrated by using a series of overlapping peptides to the CS 1 region (Fig. 1 A) (Fig. 1 A) , BSA, gelatin, and laminin (not shown).
To confirm the sequence specificity of mAb 90. 45 , peptide conjugates were used as soluble inhibitors of mAb binding to native CS1-coated ELISA plates (Fig. 1 B) . Only the peptide derived from the COOH-terminal region of CS1 specifically inhibited binding ofmAb 90.45 to native CS 1 25-mer ( Fig. 1 B,  filled circles) . In summary, we have been able to generate a panel of CS 1-specific mAbs that recognize both the CS1 peptide sequence alone, and also in the context of intact FN.
RA synovial microvasculature d ifferentially expresses alternatively spliced CSJ. To study tissue expression of FN variants generated by alternatively splicing, immunohistochemistry was performed on synovial specimens obtained from both RA (n = 10) and normal (n = 6) individuals (Fig. 2) . Sequential tissue sections from normal (Fig. 2, a, c , e, g, and i) and RA (Fig. 2, b, d , f h, andj) synovia were incubated with a panel of mAbs followed by staining using the immunoperoxidase method. Identical experimental conditions were used for both RA and normal samples, i.e., same thickness sections, mounted on the same slide, incubated with the same concentration of primary and secondary antibody, and developed for the same length of time.
The specificity of the immunoperoxidase labeling technique was first demonstrated with mAb 4C7 (specific for the A chain of human laminin [40] ), which stained distinctly the microvasculature ofboth normal and RA synovia (Fig. 2, c and  d ). This result was consistent with laminin being localized to the subendothelial basement membrane (46). Expression of FN was then analyzed using mAb 3E3, which reacts with a constant epitope on the cell attachment region of FN (41). Anti-FN mAb 3E3 uniformly stained endothelium and synovial extracellular space in both normal and RA synovia (Fig. 2 In sharp contrast, RA sections labeled with anti-CS 1 mAb 90.45 showed conspicuous staining in the endothelial lining of blood vessels (see Fig. 2 h) and in the hyperplastic layers ofthe synovial intimal lining (see Fig. 3 e) , but not in the ECM. Moreover, CS 1 immunostaining of RA microvasculature was seen with at least three additional independently derived anti-CS1 mAbs (e.g., mAb 321; see Fig. 3 d) , and could be abrogated by pretreating mAb 90.45 with soluble CS 1-C-OVA conjugate but not CS 1-N-OVA or CS 1-M-OVA (not shown), thus confirming the specificity of CS 1 staining in RA. Fig. 2, g and h, demonstrate a significant quantitative difference in blood vessel staining intensity with anti-CS 1 mAb between representative RA and normal synovial tissues, the former being strongly positive ( 10/10) and the latter being either weakly positive ( 1 /6; see Fig. 2 g) or completely negative (5/6 ). As for the intimal lining, CS1 was expressed in normal synovium on the single layer of lining cells (Fig. 2 g, bottom (Fig. 3 a) , but allowed visualization of the osmium-stained endothelial cell (EC) monolayer facing the lumen of the blood vessel with a red blood cell ghost in its proximity. In contrast, synovial tissue treated with mAbs to either PECAM-1 /CD3 1 (Fig. 3 b) or collagen type IV (Fig. 3  c) specifically stained discrete ultrastructural regions, namely, the lumenal aspect of the blood vessel endothelium (PECAM-1 /CD3 1; Fig. 3 b) and the subendothelial region (collagen type IV; Fig. 3 c) . This pattern of immunoreactivity is consistent with PECAM-1 /CD31 being an EC membrane marker (47) , and collagen type IV being a major component of the basal lamina (46) . Labeling of ultrathin synovial sections with the anti-CS1 mAb 321 (mAb 90.45 did not stain paraformaldehyde-fixed sections) showed distinct immunostaining on the lumenal plasma membrane of EC (Fig. 3 d) . In addition, anti-CS 1 also prominently stained the plasma membrane of synoviocytes in the synovial intimal lining (Fig. 3 e) , at the interface with the joint space. In sections in which membrane sloughing was observed, most ofthe immunoreactivity to CS 1 was found within EC (Fig. 3 f) , but not within a neighboring macrophage, thus suggesting that EC in RA may generate CS1-containing FN intracellularly. This observation is consistent with the ability of cultured human EC to synthesize and secrete FN (48) . In conclusion, CS1-expressing FN localizes to the lumen of EC and intimal lining synoviocytes, and could potentially mediate adhesion ofcirculating leukocytes within the RA synovial microvasculature.
Cultured human EC express CSJ-containing FN mRNA. Expression of CS 1-containing FN on the surface of EC in RA synovium raises questions about the cellular source of alternatively spliced CS 1. To determine whether human EC are capable of expressing alternatively spliced FN mRNA that includes CS 1, Northern blot analysis of human umbilical vein endothelial cell (HUVEC) mRNA was performed (Fig. 4 A) . Probes specific for CS1 (Fig. 4 A, stimulated HUVEC (Fig. 4 B) . Radiolabeled riboprobes complementary to HepII and CS1 coding strands were generated, and incubated with IL-1(3-stimulated HUVEC mRNA (see Methods). Upon treatment with RNase, only the portion of each probe specifically hybridized to mRNA is expected to remain undigested. Both probes also contained 76 bp of vectorderived flanking sequences that are noncomplementary, and thus RNase sensitive, to allow differentiation between fulllength undigested probe (see Fig. 4 (Fig. 5) . In contrast, Molt-4 cells did not attach to CS 1, unless cells were previously activated with adhesion-promoting mAb 8A2 (39, 49). Subsequently, Molt-4 attachment could also be inhibited by anti-a4 mAbs (Fig. 5) . Taken to- [23] ). Inhibition of cell attachment by mAbs was analyzed using the following reagents: control mAb LB3.1 (1 Ag/ml; anti-human class II MHC), P4C2 (0.6 ,g/ml; anti-human a4 integrin subunit), and 8A2 (1 gg/ ml; anti-human 1 integrin subunit).
gether, these results confirm the observation that functional activation of VLA-4 is required for cell adhesion to CS 1 (39, [49] [50] [51] [52] .
Both Jurkat (n = 5; Table I and Fig. 6 ), and Molt-4 (n = 3; Table I and Fig. 7) were then assayed for cell adherence on frozen RA synovial sections. Unstimulated Jurkat readily bound to the lumenal aspect of blood vessels in RA synovium, with little interstitial cell binding (Fig. 6 a) . Attachment of Jurkat cells to RA intimal synovial lining was also observed (not shown). In contrast, Jurkat cells failed to adhere to synovial blood vessels from normal tissue specimens (> 2±1 T cells bound/blood vessel; n = 2; not shown).
mAb inhibition experiments (see Table I ) showed that Jurkat intravascular adhesion was abrogated by anti-a4 mAb P4C2 (3 ,ug/ml; Table I and Fig. 6 b) , and dramatically reduced by the CS1 peptide (500 ,g/ml; Table I and Fig. 6 c) . In addition, we found that anti-CS 1 mAb 90.45 was also inhibitory in this assay (not shown). Jurkat cell binding was relatively unaffected, however, by incubation of RA sections with at least two separate mAbs to VCAM-1, namely 4B9 (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) jug/ml; this mAb blocks VLA-4-dependent adhesion to both six-and seven-Ig domain forms of VCAM-1) (37, 38) and P3H12 (10-20 ,g/ml) (see Table I and Fig. 6 d) . Neither control peptide (500 jg/ml), nor scrambled CS I peptide (500 Ag/ml) or anti-a5 mAb P1D6 (10-20 ,g/ml), had any effect on Jurkat adhesion to RA synovium (Table I) . To ensure that lack of inhibition by anti-VCAM-1 was not due to epitope loss during tissue preparation, RA synovial sections from tissue specimens used in binding assays were stained with mAbs 4B9 Fig. 7 a) , unless cells were pretreated with adhesion-promoting mAb 8A2 (Table I and Fig. 7 b) . mAb-stimulated adherence of Molt-4 cells to RA synovial endothelium was then inhibitable by anti-a4 and by CSl peptide (Table I and Fig. 7 c) , but not by control peptides (Table I) , by anti-VCAM-1 mAbs (Table I and Fig. 7 d) , or by anti-a5 (Table I). In conclusion, adherence of T cell lines to the endothelium in RA synovium requires functional activation ofVLA-4, and is primarily mediated by CS 1 on RA EC.
Discussion
We have investigated the expression and functional significance of CS 1-containing forms of FN generated by alternatively splicing in both normal and RA synovium. Our data suggest that RA, but not normal, synovial endothelium selectively expresses CS 1. Quite unexpectedly, CS 1-expressing FN molecules are found decorating the lumen of RA EC, but are totally absent on the abluminal side ofthe endothelium and in the ECM. Functionally, endothelial expression of CSl in RA synovium results in intravascular adherence of activated T lymphocytes in both a VLA-4-and CS 1-dependent fashion. These observations provide a basis for attempting to interfere with chronic accumulation of mononuclear cells in RA using CS 1-based therapeutics.
To date, much ofthe work on FN polypeptide diversity and regulation of FN gene splicing patterns has focused largely on the EIIIA and EIIIB regions (5-9, 42). However, a specific molecular interaction for either EIIIA or EIIIB and target cellular receptors remains to be defined. In contrast, expression of alternatively spliced CSl results in generation of a binding site on FN for the leukocyte integrin VLA-4 (15, 16) . Previously, the occurrence of FN variants expressing CS1 had only been surmised, mostly in cultured cell lines, by analyzing the cohort ofFN mRNA transcripts (2) (3) (4) (10) (11) (12) . In this study, availability ofspecific anti-CS 1 mAbs has allowed us to use immunohistochemical techniques to investigate expression of CS 1-containing FN in human tissues. Unlike most molecular forms of FN typically found in the ECM ( 1 ), we find that CS I is exclusively restricted to inflamed RA endothelium (Fig. 2 h) . Furthermore, CS1 expression correlates with chronic inflammation in RA, since CS I is found only rarely in normal synovial blood vessels (Fig. 2 g ). CSl immunoreactivity in RA synovium appears to be specific for this FN variant because a panel of mAbs, four to conserved epitopes on FN (41 ) and one mapping to the EIIIA region ( 1, 42) , all stain the ECM on both RA and normal synovium. Thus, our data strongly suggest that CS 1-containing FN is specifically expressed on blood vessel endothelium, but not in the ECM, and CS 1 expression correlates with the inflammatory phenotype in RA synovium.
By and large, FN is considered to be an ECM component involved in tissue organization, differentiation, and repair, even though FN can also be found in circulating plasma and other body fluids (1). Thus, lumenal expression of CS1-containing FN on EC and also synoviocytes in the intimal lining of RA synovium as shown by immunoelectron microscopy (see Fig. 3, d and e) is totally unexpected. Indeed, the endothelium is known to modulate leukocyte emigration and trafficking, especially during inflammation, through expression of a select group of cytokine-inducible transmembrane adhesion molecules, namely intercellular adhesion molecule type 1 (ICAM-1), ICAM-2, VCAM-1, and E-and P-selectins (26, 54, 55) . To our knowledge, this is the first suggestion that a matrix protein like FN may play a direct role in recruitment of circulating leukocytes to inflamed endothelium via alternatively spliced CS 1.
Since alternative splicing of FN is a process ofconsiderable biological significance, especially during embryogenesis (5, 6, 42), the observation that CS1 is selectively expressed in RA synovium suggests functional involvement for CS1 in the pathogenesis of RA. In this regard, the T cell line Jurkat was found to adhere readily to the intravascular surface ofRA synovial endothelium (see Fig. 6 a) . Based on inhibition data (see Table I ), T cell attachment appears to be mediated by the integrin VLA-4 on the lymphocyte (see Fig. 6 b) interacting with a putative CS 1-containing counterreceptor on the endothelial cell (see Fig. 6 c) . Since Jurkat adhesion to RA synovium is blocked by CSl peptide and anti-CS 1 mAb, but not by mAbs to VCAM-1 (see Table I and Fig. 6, c and d) , we conclude that a direct interaction occurs between lymphocyte VLA-4 and CS 1-containing FN expressed on RA microvasculature.
Our data also suggest that functional activation ofVLA-4 is required for efficient T cell binding to RA endothelium. While Jurkat cells express a partially activated form of VLA-4 (Fig.  5) , a separate T cell line, Molt-4, expresses VLA-4 in a functionally inactive state{ Fig. 5 ), and thus is incapable ofbinding to RA synovium (Fig. 7 a) .\ tionally activated state (39, [49] [50] [51] [52] , and this resu4A1 lWmatic augmentation of Molt-4 adherence to RA endothelium (Fig. 7 b) . mAb-stimulated attachment of Molt-4, like that of unstimulated Jurkat cells, is then inhibited by both anti-VLA-4 and CS 1 peptide, but remains unaffected by mAbs to VCAM-1 (see Table I and Figs. 7, c and d). Consequently, T cell adherence to RA endothelium requires prior functional activation of leukocyte VLA-4, and is mediated by CS1 present on the lumen ofRA endothelial cells. In this regard, our results correlate nicely with analyses on the functional status of VLA-4 on T cells isolated from the synovial fluid and synovial membrane of RA patients (56, 57) . These T lymphocytes exhibit increased VLA-4-mediated adherence to both CS1 (56) and VCAM-1 (57) relative to autologous peripheral blood lymphocytes. These studies (56, 57) , as well as ours, suggest that only leukocytes expressing functionally activated VLA-4 are selectively recruited to inflammatory sites in RA.
The involvement of VLA-4 in functional interactions between leukocytes and RA synovium raises the question of which role VLA-4 ligands, i.e., CSl and VCAM-1, play in the pathogenesis of RA. To date, most studies have focused on expression of VCAM-I in RA (36, 58, 59) . VCAM-l has been found in RA synovial microvasculature (36, 58) , and in cultured fibroblast-like synoviocytes (FLS) derived from RA patients (36, 59 ). However, we have shown that small amounts of VCAM-1 are also expressed in normal synovial endothelium (36) . With regard to the functional status of VCAM-1 on RA endothelium, in vitro studies have shown that anti-VCAM-1 partially inhibits both lymphocyte adherence to synovial high endothelial venules (58) , and adhesion of T cell lines to IL-1-and IL-4-stimulated FLS from RA patients (36) . This study clearly indicates involvement of CS 1, but not VCAM-1, in lymphocyte attachment to frozen sections from synovial specimens with clinical characteristics of full-fledged RA. Since cytokines are known to induce transient expression of VCAM-1 in RA (36, 59) , it is conceivable that local and temporal changes in cytokine production within the rheumatoid joint may dictate which pathway, VLA-4/VCAM-1 or VLA-4/CS 1, predominantly operates at a given stage in synovitis. Recently, leukocyte integrins, including VLA-4, have also been implicated in monocyte recruitment in RA (60) .
Expression of CS 1-containing FN in RA raises the possibility that CS 1, and consequently FN gene splicing, may be subject to regulation by inflammatory stimuli. In this regard, transforming growth factor ,B has been shown to influence splicing (61, 62) 
